This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andersson KE, Appell R, Awad S, Chapple C, Drutz H, Finkbeiner A, Fourcroy J, Haab F, Wein A (2002) Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A (eds) Incontinence, 2nd International Consultation on Incontinence. Plymbridge Distributors, Plymouth, UK, pp 481–511
Cardozo L, Rekers H, Tapp A et al (1993) Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas 18:47–53
Chancellor M, Freedman S, Mitcheson HD et al (2000) Tolterodine, an effective and well-tolerated treatment for urge incontinence and other overactive bladder symptoms. Drug Invest 19:83–88
Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A (2004) Randomized, double-blind placebo and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310
Dmochowski R, Miklos J, Norton PA, Zinner N, Yalcin I, Bump C (2003) Duloxetine vs placebo for the treatment of north American women with stress urinary incontinence. J Urol 170:1259–1263
Fantl JA, Cardozo LD, McClish DK et al (1994) Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 83:12–18
Grady D, Brown JS, Vittinghoff E et al (2001) Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 97:116–120
Haab F, Stewart L, Dwyer P (2004) Darifenacin, an M3 selective receptor antagonist is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45:420–429
Hofner K, Halaska M, Primus G et al (2000) Tolerability and efficacy of Trospium chloride in a long-term treatment (52 weeks) in patients with urge-syndrome: a double-blind, controlled, multicentre clinical trial. Neurourol Urodyn 19:487–488
Huggins ME, Bathia N, Ostergard DR (2003) Urinary incontinence: newer pharmacotherapeutic trends. Curr Opin Obstet Gynecol 15:419–427
Madersbacher H, Halaska M, Voigt R et al (1999) A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646–651
Sultana CJ, Walters MD (1990) Estrogen and urinary incontinence in women. Maturitas 20:129–138
Thuroff JW, Bunke B, Ebner A et al (1991) Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145:813–816
Thuroff JW, Chartier-Kastler E, Corcus J et al (1998) Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 16[Suppl 1]:S48–S61
Van Kerrebroeck P, Kreder K, Jonas U et al (2001) Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57:414–421
Versi E, Appell R, Mobley D et al (2000) Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 95:718–721
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Naumann, G., Koelbl, H. (2005). Pharmacological Treatment of Urinary Incontinence. In: Becker, HD., Stenzl, A., Wallwiener, D., Zittel, T.T. (eds) Urinary and Fecal Incontinence. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27494-4_12
Download citation
DOI: https://doi.org/10.1007/3-540-27494-4_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-22225-5
Online ISBN: 978-3-540-27494-0
eBook Packages: MedicineMedicine (R0)